Researchers develop and test new molecule as a delivery vehicle to image and kill brain tumors

Glioblastomas are the most common and aggressive brain tumor in humans, with a high rate of relapse. These tumor cells often extend beyond the well-defined tumor margins making it extremely difficult for clinicians and radiologists to visualize with current imaging techniques. Researchers have been investigating enhanced methods of attacking these cells in order to possibly delay or prevent brain tumor relapse.

In a study published in the August issue of the journal Radiology, the research team led by Panos Fatouros, Ph.D., a former professor and chair of the Division of Radiation Physics and Biology in the VCU School of Medicine who retired in 2010, demonstrated that a nanoparticle containing an MRI diagnostic agent can effectively be imaged within the brain tumor and provide radiation therapy in an animal model.

The nanoparticle filled with gadolinium, a sensitive MRI contrast agent for imaging, and coupled with radioactive lutetium 177 to deliver brachytherapy, is known as a theranostic agent – a single compound capable of delivering simultaneously effective treatment and imaging. The lutetium 177 is attached to the outside of the carbon cage of the nanoparticle.

“We believe the clustering properties of this nanoplatform prolong its retention within the tumor, thereby allowing a higher radiation dose to be delivered locally,” said Michael Shultz, Ph.D., a research fellow in Fatouros' lab in the Department of Radiology in the VCU School of Medicine.

“This theranostic agent could potentially provide critical data about tumor response to therapy by means of longitudinal imaging without further contrast administration,” said Fatouros.

A nanoparticle called a functionalized metallofullerene (fMF), also known as a “buckyball,” served as the basis of this work and was created by study collaborator, Harry Dorn, Ph.D., a chemistry professor at Virginia Tech, and his team. In 1999, Dorn and his colleagues were able to encapsulate rare earth metals in the hollow interior of these nanoparticles that can easily be recognized by MRI techniques.

“Although this is a limited animal study, it shows great promise and hopefully this metallofullerene platform will be extended to humans,” said Dorn.

Fatouros, who is the corresponding author on the study, Shultz and Dorn collaborated with John D. Wilson, Ph.D., associate professor in the VCU Department of Radiology; Christine E. Fuller, M.D., professor and director of neuropathology and autopsy pathology at VCU; and Jianyuan “Jason” Zhang, a graduate student in chemistry at Virginia Tech from Beijing, China.

The study was funded by grants to Fatouros from the National Institutes of Health's National Cancer Institute, and to Dorn from the National Science Foundation.

EDITOR'S NOTE: A copy of the study is available for reporters by email request from lbrooks@rsna.org.

About VCU and the VCU Medical Center: Virginia Commonwealth University is a major, urban public research university with national and international rankings in sponsored research. Located on two downtown campuses in Richmond, VCU enrolls more than 32,000 students in 211 certificate and degree programs in the arts, sciences and humanities. Sixty-nine of the programs are unique in Virginia, many of them crossing the disciplines of VCU's 13 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonwealth University compose the VCU Medical Center, one of the nation's leading academic medical centers.